{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:13:37Z","timestamp":1790806417272,"version":"4.1.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40259-023-00613-6","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T09:02:24Z","timestamp":1688029344000},"page":"813-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment with Biologic Drugs in Pediatric Beh\u00e7et\u2019s Disease: A Comprehensive Analysis of the Published Data"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1065-2363","authenticated-orcid":false,"given":"Ezgi Deniz","family":"Batu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-8996","authenticated-orcid":false,"given":"Seher","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6629-3967","authenticated-orcid":false,"given":"Veysel","family":"Cam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-7387","authenticated-orcid":false,"given":"Nuray","family":"Aktay Ayaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-7282","authenticated-orcid":false,"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"issue":"1","key":"613_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","volume":"7","author":"Y Yazici","year":"2021","unstructured":"Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, et al. Behcet syndrome. Nat Rev Dis Primers. 2021;7(1):67.","journal-title":"Nat Rev Dis Primers"},{"key":"613_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/TCRM.S232660","volume":"16","author":"G Costagliola","year":"2020","unstructured":"Costagliola G, Cappelli S, Consolini R. Beh\u00e7et's disease in children: diagnostic and management challenges. Ther Clin Risk Manag. 2020;16:495\u2013507.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"613_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00296-018-4208-9","volume":"39","author":"ED Batu","year":"2019","unstructured":"Batu ED. Diagnostic\/classification criteria in pediatric Behcet\u2019s disease. Rheumatol Int. 2019;39(1):37\u201346.","journal-title":"Rheumatol Int"},{"issue":"5","key":"613_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/BOR.0b013e32833cc9b7","volume":"22","author":"S Ozen","year":"2010","unstructured":"Ozen S. Pediatric onset Behcet disease. Curr Opin Rheumatol. 2010;22(5):585\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"613_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.semarthrit.2020.01.013","volume":"50","author":"Y Butbul Aviel","year":"2020","unstructured":"Butbul Aviel Y, Batu ED, Sozeri B, Aktay Ayaz N, Baba L, Amarilyo G, et al. Characteristics of pediatric Behcet\u2019s disease in Turkey and Israel: a cross-sectional cohort comparison. Semin Arthritis Rheum. 2020;50(3):515\u201320.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"613_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaad.2007.10.452","volume":"58","author":"Y Karincaoglu","year":"2008","unstructured":"Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunasti S, et al. Demographic and clinical properties of juvenile-onset Behcet\u2019s disease: a controlled multicenter study. J Am Acad Dermatol. 2008;58(4):579\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"613_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12016-020-08809-2","volume":"61","author":"YC Hu","year":"2021","unstructured":"Hu YC, Chiang BL, Yang YH. Clinical manifestations and management of pediatric Behcet\u2019s disease. Clin Rev Allergy Immunol. 2021;61(2):171\u201380.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"613_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5152\/eurjrheum.2020.20138","volume":"8","author":"F Alibaz-Oner","year":"2021","unstructured":"Alibaz-Oner F, Direskeneli H. Biologic treatments in Behcet\u2019s disease. Eur J Rheumatol. 2021;8(4):217\u201322.","journal-title":"Eur J Rheumatol"},{"issue":"6","key":"613_CR9","first-page":"808","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"613_CR10","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.2169\/internalmedicine.4705-20","volume":"59","author":"S Hirohata","year":"2020","unstructured":"Hirohata S, Kikuchi H, Sawada T, Okada M, Takeno M, Kuwana M, et al. Recommendations for the management of neuro-Behcet\u2019s disease by the Japanese National Research Committee for Behcet\u2019s Disease. Intern Med. 2020;59(19):2359\u201367.","journal-title":"Intern Med"},{"key":"613_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road002","author":"H Nagafuchi","year":"2023","unstructured":"Nagafuchi H, Kikuchi H, Ishibash H, Maeda H, Ogino H, Kirino Y, et al. Recommendations for the management of the vascular involvement in Behcet\u2019s disease by the Japanese National Research Committee for Behcet\u2019s Disease: secondary publication. Mod Rheumatol. 2023. https:\/\/doi.org\/10.1093\/mr\/road002.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"613_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1346-8138.15207","volume":"47","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Iwata Y, Asai J, Kawakami T, Tsunemi Y, Takeuchi M, et al. Guidelines for the treatment of skin and mucosal lesions in Behcet\u2019s disease: a secondary publication. J Dermatol. 2020;47(3):223\u201335.","journal-title":"J Dermatol"},{"issue":"7","key":"613_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","volume":"55","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K, Nagahori M, et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Behcet\u2019s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. J Gastroenterol. 2020;55(7):679\u2013700.","journal-title":"J Gastroenterol"},{"issue":"Suppl. 1","key":"613_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13023-020-01620-4","volume":"16","author":"I Kone-Paut","year":"2021","unstructured":"Kone-Paut I, Barete S, Bodaghi B, Deiva K, Desbois AC, Galeotti C, et al. French recommendations for the management of Behcet\u2019s disease. Orphanet J Rare Dis. 2021;16(Suppl. 1):352.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"613_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E Alpsoy","year":"2002","unstructured":"Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467\u201371.","journal-title":"Arch Dermatol"},{"issue":"3","key":"613_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246\u201352.","journal-title":"Int J Rheum Dis"},{"issue":"20","key":"613_CR17","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers in Behcet\u2019s syndrome. N Engl J Med. 2019;381(20):1918\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"613_CR18","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98\u2013105.","journal-title":"J Rheumatol"},{"issue":"1","key":"613_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.","journal-title":"Syst Rev"},{"issue":"3","key":"613_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","volume":"26","author":"AM Abu El-Asrar","year":"2005","unstructured":"Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet\u2019s disease. Int Ophthalmol. 2005;26(3):83\u201392.","journal-title":"Int Ophthalmol"},{"issue":"8","key":"613_CR21","first-page":"485","volume":"15","author":"Z Al Mosawi","year":"2012","unstructured":"Al Mosawi Z, Madan W, Farid E. Pediatric-onset Behcet disease in Bahrain: report of nine cases and literature review. Arch Iran Med. 2012;15(8):485\u20137.","journal-title":"Arch Iran Med"},{"issue":"6","key":"613_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09273948.2013.779727","volume":"21","author":"S Al Rashidi","year":"2013","unstructured":"Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21(6):468\u201374.","journal-title":"Ocul Immunol Inflamm"},{"key":"613_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101027","volume":"21","author":"A Al-Moujahed","year":"2021","unstructured":"Al-Moujahed A, Hien DL, Akhavanrezayat A, Pham BH, Tuong Ngoc TT, Doan HL, et al. Reperfusion of retinal ischemia in retinal occlusive vasculitis with nicotinic acid and infliximab in Adamantiades-Behcet\u2019s disease. Am J Ophthalmol Case Rep. 2021;21: 101027.","journal-title":"Am J Ophthalmol Case Rep."},{"issue":"4","key":"613_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5606\/ArchRheumatol.2019.7169","volume":"34","author":"N Aladag Ciftdemir","year":"2019","unstructured":"Aladag Ciftdemir N, Gokalp S, Eren T. Is Immunosuppressive and thrombolytic therapy really effective in a patient with intracardiac thrombosis and pulmonary artery aneurysm due to Behcet\u2019s disease? Arch Rheumatol. 2019;34(4):451\u20136.","journal-title":"Arch Rheumatol."},{"issue":"5","key":"613_CR25","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","volume":"57","author":"B Atienza-Mateo","year":"2018","unstructured":"Atienza-Mateo B, Calvo-Rio V, Beltran E, Martinez-Costa L, Valls-Pascual E, Hernandez-Garfella M, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet\u2019s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"613_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1177\/0883073808318199","volume":"23","author":"M Atkinson","year":"2008","unstructured":"Atkinson M, Moore E, Altinok D, Acsadi G. Cerebral infarct in pediatric neuro-Beh\u00e7et\u2019s disease. J Child Neurol. 2008;23(11):1331\u20135.","journal-title":"J Child Neurol"},{"issue":"4","key":"613_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/09273948.2019.1611875","volume":"28","author":"M Balbaba","year":"2020","unstructured":"Balbaba M, Ulas F, Postaci SA, Celiker U, Gurgoze MK. Clinical and demographic features of pediatric-onset Behcet\u2019s disease and evaluation of optical coherence tomography findings. Ocul Immunol Inflamm. 2020;28(4):606\u201312.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"613_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","volume":"29","author":"Y Bilginer","year":"2010","unstructured":"Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet\u2019s disease. Clin Rheumatol. 2010;29(2):209\u201310.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"613_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/09273940701299370","volume":"15","author":"RR Buggage","year":"2007","unstructured":"Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet\u2019s disease. Ocul Immunol Inflamm. 2007;15(2):63\u201370.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"613_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.5606\/ArchRheumatol.2019.7253","volume":"34","author":"M Cakan","year":"2019","unstructured":"Cakan M, Yildiz Ekinci D, Gul Karadag S, Aktay AN. Etiologic spectrum and follow-up results of noninfectious uveitis in children: a single referral center experience. Arch Rheumatol. 2019;34(3):294\u2013300.","journal-title":"Arch Rheumatol."},{"issue":"2","key":"613_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/039463200902200235","volume":"22","author":"L Cantarini","year":"2009","unstructured":"Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M. Safety and efficacy of etanercept in children with juvenile-onset Behcet\u2019s disease. Int J Immunopathol Pharmacol. 2009;22(2):551\u20135.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"613_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/039463201402700316","volume":"27","author":"S Caporuscio","year":"2014","unstructured":"Caporuscio S, Pranteda G, Nistico S, Maucione T, Canzoni M, Stefani A, et al. An incomplete form of childhood Beh\u00e7et\u2019s disease treated with infliximab. Int J Immunopathol Pharmacol. 2014;27(3):445\u20138.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"613_CR33","first-page":"179","volume":"54","author":"MS Cirkinoglu","year":"2019","unstructured":"Cirkinoglu MS, Demir S, Bilginer Y, Ozen S. Behcet\u2019s disease in children: single-center experience. Turk Pediatri Ars. 2019;54(3):179\u201384.","journal-title":"Turk Pediatri Ars."},{"issue":"4","key":"613_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00417-018-3928-6","volume":"256","author":"I Deitch","year":"2018","unstructured":"Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R, Neumann R, et al. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):801\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"613_CR35","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0162","volume":"144","author":"S Demir","year":"2019","unstructured":"Demir S, Sag E, Kaya Akca U, Hazirolan T, Bilginer Y, Ozen S. The challenge of treating pulmonary vasculitis in Behcet disease: two pediatric cases. Pediatrics. 2019;144(2): e20190162.","journal-title":"Pediatrics"},{"issue":"1","key":"613_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10067-021-05896-0","volume":"41","author":"Z Ekici Tekin","year":"2022","unstructured":"Ekici Tekin Z, Celikel E, Aydin F, Kurt T, Sezer M, Tekgoz N, et al. Juvenile Behcet\u2019s disease: a tertiary center experience. Clin Rheumatol. 2022;41(1):187\u201394.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"613_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/1744666X.2021.1834853","volume":"16","author":"RMK Ekinci","year":"2020","unstructured":"Ekinci RMK, Esen E, Erol AH, Sizmaz S, Karagoz D, Altintas DU, et al. Evaluation of different classification criteria in children with Behcet disease: results from a single referral center. Expert Rev Clin Immunol. 2020;16(11):1093\u20137.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"613_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/rheumatology\/kep148","volume":"48","author":"D Eleftheriou","year":"2009","unstructured":"Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford). 2009;48(8):978\u201386.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"613_CR39","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10067-006-0426-8","volume":"26","author":"LM Endo","year":"2007","unstructured":"Endo LM, Rowe SM, Romp RL, Buckmaster MA, Atkinson TP. Pulmonary aneurysms and intracardiac thrombi due to Behcet\u2019s disease in an African-American adolescent with oculocutaneous albinism. Clin Rheumatol. 2007;26(9):1537\u20139.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"613_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaapos.2005.04.005","volume":"9","author":"R Friling","year":"2005","unstructured":"Friling R, Kramer M, Snir M, Axer-Siegel R, Weinberger D, Mukamel M. Clinical course and outcome of uveitis in children. J AAPOS. 2005;9(4):379\u201382.","journal-title":"J AAPOS"},{"issue":"1","key":"613_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13052-017-0350-3","volume":"43","author":"R Gallizzi","year":"2017","unstructured":"Gallizzi R, De Vivo D, Valenti S, Pidone C, Romeo C, Caruso R, et al. Intestinal and neurological involvement in Behcet disease: a clinical case. Ital J Pediatr. 2017;43(1):33.","journal-title":"Ital J Pediatr"},{"issue":"1","key":"613_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12969-017-0213-x","volume":"15","author":"R Gallizzi","year":"2017","unstructured":"Gallizzi R, Pidone C, Cantarini L, Finetti M, Cattalini M, Filocamo G, et al. A national cohort study on pediatric Behcet\u2019s disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J. 2017;15(1):84.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"613_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12969-021-00552-y","volume":"19","author":"M Girardelli","year":"2021","unstructured":"Girardelli M, Valencic E, Moressa V, Margagliotta R, Tesser A, Pastore S, et al. Genetic and immunologic findings in children with recurrent aphthous stomatitis with systemic inflammation. Pediatr Rheumatol Online J. 2021;19(1):70.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"613_CR44","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/rheumatology\/kem199","volume":"46","author":"S Guillaume-Czitrom","year":"2007","unstructured":"Guillaume-Czitrom S, Berger C, Pajot C, Bodaghi B, Wechsler B, Kone-Paut I. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet\u2019s disease. Rheumatology (Oxford). 2007;46(10):1570\u20133.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"613_CR45","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/MPH.0000000000000830","volume":"39","author":"A Gurunathan","year":"2017","unstructured":"Gurunathan A, Teachey DT, Chikwava KR, Witmer C, Desai AV. Behcet disease initially presenting as deep venous thrombosis: a case report. J Pediatr Hematol Oncol. 2017;39(5):410\u20132.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"613_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.reuma.2013.05.007","volume":"10","author":"DO Hacihamdioglu","year":"2014","unstructured":"Hacihamdioglu DO, Demiriz M, Sobaci G, Kocaoglu M, Demirkaya E, Gok F. Cerebral vein thrombosis in a four year old with Behcet\u2019s disease. Reumatol Clin. 2014;10(4):254\u20136.","journal-title":"Reumatol Clin."},{"issue":"12","key":"613_CR47","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1007\/s10620-018-5248-4","volume":"63","author":"S Hakim","year":"2018","unstructured":"Hakim S, Ramireddy S, Amin M, Gebara S, Cappell MS. Preoperative misdiagnosis of intestinal Behcet\u2019s syndrome as Crohn\u2019s disease based on superficial colonoscopic biopsies: case report and systematic review. Dig Dis Sci. 2018;63(12):3509\u201315.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"613_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5455\/msm.2021.33.78-81","volume":"33","author":"M Halilbasic","year":"2021","unstructured":"Halilbasic M, Vodencarevic AN, Cosickic A, Halilbasic A, Cabric A. Adalimumab in treatment of uveitis in pediatric Behcet\u2019s disease: a case report. Mater Sociomed. 2021;33(1):78\u201381.","journal-title":"Mater Sociomed."},{"issue":"1","key":"613_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12969-019-0333-6","volume":"17","author":"T Hiyama","year":"2019","unstructured":"Hiyama T, Harada Y, Doi T, Kiuchi Y. Early administration of adalimumab for paediatric uveitis due to Behcet\u2019s disease. Pediatr Rheumatol Online J. 2019;17(1):29.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"613_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12348-019-0181-z","volume":"9","author":"M Ho","year":"2019","unstructured":"Ho M, Chen LJ, Sin HPY, Iu LPL, Brelen M, Ho ACH, et al. Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet\u2019s disease-related uveitis. J Ophthalmic Inflamm Infect. 2019;9(1):14.","journal-title":"J Ophthalmic Inflamm Infect."},{"issue":"1","key":"613_CR51","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12887-019-1613-5","volume":"19","author":"YC Hu","year":"2019","unstructured":"Hu YC, Yang YH, Lin YT, Wang LC, Yu HH, Lee JH, et al. Clinical manifestations and anti-TNF alpha therapy of juvenile Behcet\u2019s disease in Taiwan. BMC Pediatr. 2019;19(1):232.","journal-title":"BMC Pediatr"},{"issue":"4 Suppl. 84","key":"613_CR52","first-page":"S58","volume":"32","author":"E Interlandi","year":"2014","unstructured":"Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Beh\u00e7et\u2019s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32(4 Suppl. 84):S58-62.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"613_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.24953\/turkjped.2019.04.016","volume":"61","author":"E Isiyel","year":"2019","unstructured":"Isiyel E, Bakkaloglu S, Oguz D, Yenicesu I, Boyunaga O, Ozdemir Y, et al. An adolescent case of extensive Behcet's disease successfully treated with infliximab. Turk J Pediatr. 2019;61(4):585\u20138.","journal-title":"Turk J Pediatr"},{"issue":"7","key":"613_CR54","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00417-011-1908-1","volume":"250","author":"D Iwata","year":"2012","unstructured":"Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behcet\u2019s disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012;250(7):1081\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"613_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1546-0096-10-2","volume":"10","author":"PJ Kahn","year":"2012","unstructured":"Kahn PJ, Yazici Y, Argilla M, Srichai M, Levy DM. Asymptomatic giant coronary aneurysm in an adolescent with Behcet\u2019s syndrome. Pediatr Rheumatol Online J. 2012;10:2.","journal-title":"Pediatr Rheumatol Online J"},{"key":"613_CR56","volume":"2015","author":"M Kaji","year":"2015","unstructured":"Kaji M, Kishi T, Miyamae T, Nagata S, Yamanaka H, Fujikawa S. Efficacy of adalimumab in a girl with refractory intestinal Behcet\u2019s disease. Case Rep Rheumatol. 2015;2015: 716138.","journal-title":"Case Rep Rheumatol."},{"issue":"4","key":"613_CR57","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/j.jinf.2005.07.026","volume":"52","author":"B Kara","year":"2006","unstructured":"Kara B, Somer A, Piskin S, Aydinli N, Salman N, Yalcin I. Neuro-Behcet syndrome presenting as acute meningeal syndrome. J Infect. 2006;52(4):e120\u20133.","journal-title":"J Infect"},{"issue":"4","key":"613_CR58","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/bjophthalmol-2015-308194","volume":"101","author":"H Keino","year":"2017","unstructured":"Keino H, Watanabe T, Taki W, Nakayama M, Nakamura T, Yan K, et al. Clinical features of uveitis in children and adolescents at a tertiary referral centre in Tokyo. Br J Ophthalmol. 2017;101(4):406\u201310.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"613_CR59","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/bjo.2008.154476","volume":"93","author":"N Kitaichi","year":"2009","unstructured":"Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S. Low prevalence of juvenile-onset Behcet\u2019s disease with uveitis in East\/South Asian people. Br J Ophthalmol. 2009;93(11):1428\u201330.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"613_CR60","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/eye.2008.397","volume":"23","author":"M Kramer","year":"2009","unstructured":"Kramer M, Amer R, Mukamel M, Snir M, Jaouni T, Friling R. Uveitis in juvenile Behcet\u2019s disease: clinical course and visual outcome compared with adult patients. Eye (Lond). 2009;23(11):2034\u201341.","journal-title":"Eye (Lond)"},{"issue":"1","key":"613_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.03.017","volume":"47","author":"H Kubo","year":"2017","unstructured":"Kubo H, Ouchi K, Nakagawa N, Akioka S. Evidence for choosing biologic disease-modifying anti-rheumatic drugs in the treatment of Behcet disease. Semin Arthritis Rheum. 2017;47(1): e1.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"613_CR62","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/rheumatology\/ken172","volume":"47","author":"JB Kuemmerle-Deschner","year":"2008","unstructured":"Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, Zierhut M, Batra M, Koetter I. Interferon-alpha: a new therapeutic option in refractory juvenile Behcet\u2019s disease with CNS involvement. Rheumatology (Oxford). 2008;47(7):1051\u20133.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"613_CR63","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5217\/ir.2017.15.3.422","volume":"15","author":"KI Lim","year":"2017","unstructured":"Lim KI, Yang DH, Ryoo E. Behcet\u2019s disease with multiple splenic abscesses in a child. Intest Res. 2017;15(3):422\u20138.","journal-title":"Intest Res"},{"key":"613_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.695197","volume":"8","author":"J Liu","year":"2021","unstructured":"Liu J, Yu X, Li C, Wang Y, Yu W, Shen M, et al. Behcet\u2019s syndrome in a Chinese pedigree of NLRP3-associated autoinflammatory disease: a coexistence or novel presentation? Front Med (Lausanne). 2021;8: 695197.","journal-title":"Front Med (Lausanne)."},{"issue":"5","key":"613_CR65","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.55563\/clinexprheumatol\/9moyyx","volume":"39","author":"I Maccora","year":"2021","unstructured":"Maccora I, Alletto A, Russo ML, Vasarri P, Simonini G. Cerebral venous thrombosis in a child with Beh\u00e7et\u2019s disease: a complication to bear in mind also in children. Clin Exp Rheumatol. 2021;39(5):S141\u20132.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"613_CR66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/09273948.2017.1332228","volume":"27","author":"NN Markomichelakis","year":"2019","unstructured":"Markomichelakis NN, Aissopou EK, Maselos S, Tugal-Tutkun I, Sfikakis PP. Biologic treatment options for retinal neovascularization in Behcet\u2019s disease. Ocul Immunol Inflamm. 2019;27(1):51\u20137.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"613_CR67","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2022.12.e29","volume":"12","author":"ML Marques","year":"2022","unstructured":"Marques ML, Cunha IM, Alves S, Guedes M, Zilhao C. Systemic autoinflammatory diseases in pediatric population. Asia Pac Allergy. 2022;12(3): e29.","journal-title":"Asia Pac Allergy"},{"issue":"1","key":"613_CR68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13052-016-0291-2","volume":"42","author":"M Marsili","year":"2016","unstructured":"Marsili M, Marzetti V, Lucantoni M, Lapergola G, Gattorno M, Chiarelli F, et al. Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behcet disease responding to adalimumab: a case report. Ital J Pediatr. 2016;42(1):81.","journal-title":"Ital J Pediatr"},{"issue":"5","key":"613_CR69","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1055\/s-0030-1269909","volume":"41","author":"J Metreau-Vastel","year":"2010","unstructured":"Metreau-Vastel J, Mikaeloff Y, Tardieu M, Kone-Paut I, Tran TA. Neurological involvement in paediatric Behcet\u2019s disease. Neuropediatrics. 2010;41(5):228\u201334.","journal-title":"Neuropediatrics"},{"issue":"10","key":"613_CR70","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s10067-016-3187-z","volume":"35","author":"S Nanthapisal","year":"2016","unstructured":"Nanthapisal S, Klein NJ, Ambrose N, Eleftheriou D, Brogan PA. Paediatric Behcet\u2019s disease: a UK tertiary centre experience. Clin Rheumatol. 2016;35(10):2509\u201316.","journal-title":"Clin Rheumatol"},{"key":"613_CR71","doi-asserted-by":"crossref","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M; Ocular Behcet\u2019s Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130(5):592\u20138.","DOI":"10.1001\/archophthalmol.2011.2698"},{"issue":"7","key":"613_CR72","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/rheumatology\/kev197","volume":"54","author":"I Pagnini","year":"2015","unstructured":"Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R. Successful treatment with canakinumab of a paediatric patient with resistant Behcet\u2019s disease. Rheumatology (Oxford). 2015;54(7):1327\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"613_CR73","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1093\/rheumatology\/keab084","volume":"60","author":"CE Pain","year":"2021","unstructured":"Pain CE, Beresford MW, Fortune F, Lai ETC, Murphy R, Taylor-Robinson D, et al. Behcet\u2019s syndrome in children and young people in the United Kingdom and the Republic of Ireland: a prospective epidemiological study. Rheumatology (Oxford). 2021;60(10):4728\u201336.","journal-title":"Rheumatology (Oxford)"},{"key":"613_CR74","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1752-1947-5-81","volume":"5","author":"F Parentin","year":"2011","unstructured":"Parentin F, Lepore L, Rabach I, Pensiero S. Paediatric Behcet\u2019s disease presenting with recurrent papillitis and episcleritis: a case report. J Med Case Rep. 2011;5:81.","journal-title":"J Med Case Rep"},{"issue":"9","key":"613_CR75","doi-asserted-by":"publisher","first-page":"NP86","DOI":"10.1177\/0883073813504137","volume":"29","author":"P Patel","year":"2014","unstructured":"Patel P, Steinschneider M, Boneparth A, Lantos G. Neuro-Behcet disease presenting with acute psychosis in an adolescent. J Child Neurol. 2014;29(9):NP86-91.","journal-title":"J Child Neurol"},{"issue":"6","key":"613_CR76","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00296-019-04300-0","volume":"39","author":"D Poddighe","year":"2019","unstructured":"Poddighe D, Mukusheva Z, Dauyey K, Assylbekova M. Adalimumab in the treatment of pediatric Behcet\u2019s disease: case-based review. Rheumatol Int. 2019;39(6):1107\u201312.","journal-title":"Rheumatol Int"},{"issue":"3","key":"613_CR77","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000509158","volume":"11","author":"G Rabina","year":"2020","unstructured":"Rabina G, Amarilyo G, Zur D, Harel L, Habot-Wilner Z. Recurrent neuroretinitis: a unique presentation of Behcet\u2019s disease in a child. Case Rep Ophthalmol. 2020;11(3):516\u201322.","journal-title":"Case Rep Ophthalmol."},{"issue":"4","key":"613_CR78","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pediatrneurol.2010.04.021","volume":"43","author":"AB Robinson","year":"2010","unstructured":"Robinson AB, Gallentine WB, Rabinovich CE. Pediatric neuro-Behcet\u2019s disease responsive to adalimumab. Pediatr Neurol. 2010;43(4):291\u20133.","journal-title":"Pediatr Neurol"},{"key":"613_CR79","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood-2003-10-3617","volume":"103","author":"G Rossi","year":"2004","unstructured":"Rossi G, Moretta A, Locatelli F. Autologous hematopoietic stem cell transplantation for severe\/refractory intestinal Beh\u00e7et disease. Blood. 2004;103:748\u201350.","journal-title":"Blood"},{"issue":"9","key":"613_CR80","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.4103\/ijo.IJO_966_20","volume":"68","author":"S Sadhu","year":"2020","unstructured":"Sadhu S, Dutta Majumder P, Biswas J. Biological therapy in refractory cases of uveitis and scleritis: an analysis of 18 cases from a tertiary eye care center from South India. Indian J Ophthalmol. 2020;68(9):1929\u201333.","journal-title":"Indian J Ophthalmol"},{"key":"613_CR81","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpeds.2017.03.052","volume":"186","author":"E Sardar","year":"2017","unstructured":"Sardar E, Dusser P, Rousseau A, Bodaghi B, Labetoulle M, Kone-Paut I. Retrospective study evaluating treatment decisions and outcomes of childhood uveitis not associated with juvenile idiopathic arthritis. J Pediatr. 2017;186:131-7.e1.","journal-title":"J Pediatr"},{"issue":"2","key":"613_CR82","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/mrcr\/rxac020","volume":"6","author":"N Sato","year":"2022","unstructured":"Sato N, Yamaide F, Shibata R, Nakano T, Yamaide A, Saito T, et al. Successful management of a case of intestinal Behcet\u2019s disease with a splenic abscess by intensified immunosuppressive therapy without splenectomy. Mod Rheumatol Case Rep. 2022;6(2):266\u20139.","journal-title":"Mod Rheumatol Case Rep."},{"issue":"4","key":"613_CR83","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.11204","volume":"49","author":"FT Saulsbury","year":"2003","unstructured":"Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behcet\u2019s disease. Arthritis Rheum. 2003;49(4):599\u2013600.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"613_CR84","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","volume":"45","author":"RK Saurenmann","year":"2006","unstructured":"Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45(8):982\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"613_CR85","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/rheumatology\/kem103","volume":"46","author":"E Seyahi","year":"2007","unstructured":"Seyahi E, Hamuryudan V, Hatemi G, Melikoglu M, Celik S, Fresko I, et al. Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet\u2019s syndrome. Rheumatology (Oxford). 2007;46(7):1213\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"613_CR86","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/acr.20404","volume":"63","author":"G Simonini","year":"2011","unstructured":"Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612\u20138.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"613_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1546-0096-11-16","volume":"11","author":"G Simonini","year":"2013","unstructured":"Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Parentin F, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-\u03b1 therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11(1):1\u20137.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"613_CR88","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1093\/rheumatology\/ken298","volume":"47","author":"G Simonini","year":"2008","unstructured":"Simonini G, Zannin ME, Caputo R, Falcini F, de Martino M, Zulian F, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008;47(10):1510\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"613_CR89","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/1756-185X.14050","volume":"24","author":"HE Sonmez","year":"2021","unstructured":"Sonmez HE, Koc R, Karadag SG, Aktay AN. The readiness of pediatric rheumatology patients and their parents to transition to adult-oriented treatment. Int J Rheum Dis. 2021;24(3):397\u2013401.","journal-title":"Int J Rheum Dis"},{"key":"613_CR90","doi-asserted-by":"publisher","unstructured":"Sonmez HK, Evereklioglu C, Gulmez Sevim D. Prompt and sustained suppression of intraocular inflammation with adalimumab in pediatric patients with non-infectious uveitis resistant to traditional managements: a 6-month follow-up research. Ocul Immunol Inflamm. 2022; p. 1\u20135. https:\/\/doi.org\/10.1080\/09273948.2022.2139274","DOI":"10.1080\/09273948.2022.2139274"},{"issue":"4","key":"613_CR91","doi-asserted-by":"publisher","first-page":"907","DOI":"10.55563\/clinexprheumatol\/r4gnxm","volume":"39","author":"B Sozeri","year":"2021","unstructured":"Sozeri B, Kardes E, Sali E, Cakir D, Demir F. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis. Clin Exp Rheumatol. 2021;39(4):907\u201312.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"613_CR92","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0002-9394(03)00791-8","volume":"136","author":"I Tugal-Tutkun","year":"2003","unstructured":"Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behcet disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003;136(6):1114\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"613_CR93","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/jop.2020.0081","volume":"37","author":"G Ucan Gunduz","year":"2021","unstructured":"Ucan Gunduz G, Yalcinbayir O, Cekic S, Yildiz M, Kilic SS. Anti-tumor necrosis factor treatment in the management of pediatric noninfectious uveitis: infliximab versus adalimumab. J Ocul Pharmacol Ther. 2021;37(4):236\u201340.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"613_CR94","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MPG.0b013e3181346b60","volume":"46","author":"M Ugras","year":"2008","unstructured":"Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Beh\u00e7et disease when other therapies fail. J Pediatr Gastroenterol Nutr. 2008;46(2):212\u20135.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"9","key":"613_CR95","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet\u2019s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71(9):1589\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"613_CR96","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.semarthrit.2003.12.005","volume":"33","author":"I Uthman","year":"2004","unstructured":"Uthman I, Mroueh K, Arayssi T, Nasr F, Masri AF. The use of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis in Lebanon. Semin Arthritis Rheum. 2004;33(6):422\u20133.","journal-title":"Semin Arthritis Rheum"},{"key":"613_CR97","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","volume":"7","author":"A Vitale","year":"2016","unstructured":"Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. 2016;7:380.","journal-title":"Front Pharmacol"},{"issue":"7","key":"613_CR98","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/jocs.14610","volume":"35","author":"AS Wang","year":"2020","unstructured":"Wang AS, Rosenzweig EB, Takeda K. A rare childhood case of Behcet\u2019s disease and chronic thromboembolic pulmonary hypertension. J Card Surg. 2020;35(7):1669\u201372.","journal-title":"J Card Surg"},{"issue":"12","key":"613_CR99","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00296-012-2628-5","volume":"33","author":"S Watanabe","year":"2013","unstructured":"Watanabe S, Aizawa-Yashiro T, Tsuruga K, Kinjo M, Ito E, Tanaka H. A young girl with refractory intestinal Behcet\u2019s disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int. 2013;33(12):3105\u20138.","journal-title":"Rheumatol Int"},{"issue":"6","key":"613_CR100","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10067-006-0212-7","volume":"26","author":"Z Yuksel","year":"2007","unstructured":"Yuksel Z, Schweizer JJ, Mourad-Baars PE, Sukhai RN, Mearin LM. A toddler with recurrent oral and genital ulcers. Clin Rheumatol. 2007;26(6):969\u201370.","journal-title":"Clin Rheumatol"},{"key":"613_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.769096","volume":"9","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Luo Y, Zhou J, Zhou S, Wang Z. The twists and turns of diagnosis and treatment of pediatric neuro-Behcet\u2019s disease: a case report and literature review. Front Pediatr. 2021;9: 769096.","journal-title":"Front Pediatr"},{"issue":"6","key":"613_CR102","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/MPG.0b013e318223652f","volume":"53","author":"I Iwama","year":"2011","unstructured":"Iwama I, Kagimoto S. Anti-tumor necrosis factor monoclonal antibody therapy for intestinal Beh\u00e7et disease in an adolescent. J Pediatr Gastroenterol Nutr. 2011;53(6):686\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6 Suppl. 94","key":"613_CR103","first-page":"S129","volume":"33","author":"I Hatemi","year":"2015","unstructured":"Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Beh\u00e7et\u2019s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl. 94):S129\u201337.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"613_CR104","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1136\/bjo.2007.127522","volume":"92","author":"C Evereklioglu","year":"2008","unstructured":"Evereklioglu C, Borlu M. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha. Br J Ophthalmol. 2008;92(8):1034 (148\u20139).","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"613_CR105","first-page":"485","volume":"15","author":"ZS Al Mosawi","year":"2012","unstructured":"Al Mosawi ZS, Madan W, Fareed E. Pediatric-onset Behcet disease in Bahrain: report of nine cases and literature review. Arch Iran Med. 2012;15(8):485\u20137.","journal-title":"Arch Iran Med"},{"issue":"5","key":"613_CR106","doi-asserted-by":"publisher","first-page":"813","DOI":"10.18240\/ijo.2022.05.19","volume":"15","author":"S Abolhasani","year":"2022","unstructured":"Abolhasani S, Khabbazi A, Hosseini F, Gholizadeh-Ghaleh Aziz S, Alipour S. Effects of anti-TNF biologic drugs on uveitis severity in Behcet patients: systematic review and meta-analysis. Int J Ophthalmol. 2022;15(5):813\u20139.","journal-title":"Int J Ophthalmol"},{"key":"613_CR107","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3389\/fphar.2020.00941","volume":"11","author":"Y Hu","year":"2020","unstructured":"Hu Y, Huang Z, Yang S, Chen X, Su W, Liang D. Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets\u2019 disease-associated uveitis: a systematic review and meta-analysis. Front Pharmacol. 2020;11:941.","journal-title":"Front Pharmacol"},{"issue":"5","key":"613_CR108","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3899\/jrheum.200300","volume":"48","author":"JL Martin-Varillas","year":"2021","unstructured":"Martin-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltran E, Sanchez-Burson J, Adan A, et al. Long-term follow-up and optimization of infliximab in refractory uveitis due to Behcet disease: national study of 103 white patients. J Rheumatol. 2021;48(5):741\u201350.","journal-title":"J Rheumatol"},{"issue":"2","key":"613_CR109","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3349\/ymj.2022.63.2.148","volume":"63","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Ma C, Dong R, Xiang W, Li M, Ma Z, et al. Efficacy and safety of anti-tumor necrosis factor-alpha agents for patients with intestinal Behcet\u2019s disease: a systematic review and meta-analysis. Yonsei Med J. 2022;63(2):148\u201357.","journal-title":"Yonsei Med J"},{"issue":"5","key":"613_CR110","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121(5):1088\u201394.","journal-title":"Gastroenterology"},{"issue":"3","key":"613_CR111","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/apt.15370","volume":"50","author":"J Korzenik","year":"2019","unstructured":"Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Norgard BM. Increased risk of developing Crohn\u2019s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(3):289\u201394.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"613_CR112","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3899\/jrheum.100809","volume":"38","author":"TD van Dijken","year":"2011","unstructured":"van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38(7):1441\u20136.","journal-title":"J Rheumatol"},{"issue":"5","key":"613_CR113","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1093\/rheumatology\/keab678","volume":"61","author":"JW van Straalen","year":"2022","unstructured":"van Straalen JW, Krol RM, Giancane G, Panaviene V, Ailioaie LM, Dolezalova P, et al. Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. Rheumatology (Oxford). 2022;61(5):2104\u201312.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"613_CR114","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/jcm11030631","volume":"11","author":"SM Ahn","year":"2022","unstructured":"Ahn SM, Kim M, Kim YJ, Lee Y, Kim YG. Risk of acute anterior uveitis in ankylosing spondylitis according to the type of tumor necrosis factor-alpha inhibitor and history of uveitis: a nationwide population-based study. J Clin Med. 2022;11(3):631.","journal-title":"J Clin Med"},{"issue":"2","key":"613_CR115","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40744-021-00296-x","volume":"8","author":"Y Li","year":"2021","unstructured":"Li Y, Mao X, Tang X, Mao H. Efficacy and safety of anti-TNFalpha therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatol Ther. 2021;8(2):711\u201327.","journal-title":"Rheumatol Ther."},{"issue":"10","key":"613_CR116","first-page":"CD013818","volume":"10","author":"WD Renton","year":"2022","unstructured":"Renton WD, Jung J, Palestine AG. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev. 2022;10(10):CD013818.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"613_CR117","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","volume":"71","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, Demetrio-Pablo R, Beltran E, Sanchez-Burson J, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behcet\u2019s disease, national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081\u20139. https:\/\/doi.org\/10.1002\/art.41026.","journal-title":"Arthritis Rheumatol"},{"key":"613_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.699903","volume":"12","author":"Y Qian","year":"2021","unstructured":"Qian Y, Qu Y, Gao F, Pei M, Liang A, Xiao J, et al. Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-A when combined with glucocorticoid in the treatment of refractory Behcet\u2019s uveitis: a randomized controlled prospective study. Front Pharmacol. 2021;12: 699903.","journal-title":"Front Pharmacol"},{"issue":"1","key":"613_CR119","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09273948.2017.1384026","volume":"27","author":"P Yang","year":"2019","unstructured":"Yang P, Huang G, Du L, Ye Z, Hu K, Wang C, et al. Long-term efficacy and safety of interferon alpha-2a in the treatment of Chinese patients with Behcet\u2019s uveitis not responding to conventional therapy. Ocul Immunol Inflamm. 2019;27(1):7\u201314.","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"613_CR120","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","volume":"26","author":"I Tugal-Tutkun","year":"2018","unstructured":"Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gul A. Use of gevokizumab in patients with Behcet\u2019s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023\u201333.","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"613_CR121","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/1744666X.2020.1798230","volume":"16","author":"C Gaggiano","year":"2020","unstructured":"Gaggiano C, Sota J, Gentileschi S, Caggiano V, Grosso S, Tosi GM, et al. The current status of biological treatment for uveitis. Expert Rev Clin Immunol. 2020;16(8):787\u2013811.","journal-title":"Expert Rev Clin Immunol"},{"key":"613_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100866","volume":"80","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Su G, Kijlstra A, Yang P. Activation of the interleukin-23\/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2021;80: 100866.","journal-title":"Prog Retin Eye Res"},{"key":"613_CR123","doi-asserted-by":"crossref","unstructured":"Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of\ntuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for\nRheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522\u20138","DOI":"10.1136\/ard.2009.118935"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00613-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:24:07Z","timestamp":1697559847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00613-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00613-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"15 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ezgi Deniz Batu received a payment for a speakers\u2019 bureau from Novartis. Seher Sener, Veysel Cam, and Nuray Aktay Ayaz have no conflicts of interest that are directly relevant to the content of the article. Seza Ozen received consultancy fees and payments for speakers\u2019 bureaus from Novartis and Sobi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data related to this review are presented in the article and online resources.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"No funding was received for the preparation of this review.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}